Abstract
Along with rising numbers of patients with metabolic syndrome, the prevalence of nonalcoholic fatty liver disease (NAFLD) has increased in proportion with the obesity epidemic. While there are no established treatments for NAFLD, current research is targeting new molecular mechanisms that underlie NAFLD and associated metabolic disorders. This review discusses some of these emerging molecular mechanisms and their therapeutic implications for the treatment of NAFLD. The basic research that has identified potential molecular targets for pharmacotherapy will be outlined.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Curcumin / therapeutic use
-
Fatty Acid Synthase, Type I / genetics
-
Fatty Acid Synthase, Type I / metabolism
-
Fatty Liver / drug therapy*
-
Fatty Liver / genetics
-
Fatty Liver / metabolism*
-
Fatty Liver / pathology
-
Fibric Acids / therapeutic use
-
Forkhead Box Protein O1
-
Forkhead Transcription Factors / genetics
-
Forkhead Transcription Factors / metabolism
-
Gene Expression Regulation
-
Humans
-
Lipid Metabolism / drug effects
-
Liver / drug effects
-
Liver / metabolism*
-
Liver / pathology
-
Mitochondria / drug effects
-
Mitochondria / metabolism*
-
Mitochondria / pathology
-
Non-alcoholic Fatty Liver Disease
-
PPAR gamma / genetics
-
PPAR gamma / metabolism
-
Peroxisomes / drug effects
-
Peroxisomes / metabolism*
-
Peroxisomes / pathology
-
Pregnane X Receptor
-
Protective Agents / therapeutic use*
-
Receptors, Cytoplasmic and Nuclear / genetics
-
Receptors, Cytoplasmic and Nuclear / metabolism
-
Receptors, Steroid / genetics
-
Receptors, Steroid / metabolism
-
Thiazolidinediones / therapeutic use
Substances
-
FOXO1 protein, human
-
Fibric Acids
-
Forkhead Box Protein O1
-
Forkhead Transcription Factors
-
PPAR gamma
-
Pregnane X Receptor
-
Protective Agents
-
Receptors, Cytoplasmic and Nuclear
-
Receptors, Steroid
-
Thiazolidinediones
-
farnesoid X-activated receptor
-
FASN protein, human
-
Fatty Acid Synthase, Type I
-
Curcumin